Literature DB >> 12671325

Improving patient compliance: a major goal in the management of hypertension.

Joel M Neutel1, David H G Smith.   

Abstract

The primary goal in the treatment of hypertension is to reduce the incidence of cardiovascular events in hypertensive patients. Studies performed to assess the impact of treating hypertension have revealed very disappointing reductions in the incidence of coronary heart disease. There are several reasons for these poor reductions in the incidence of cardiovascular disease; however, the most important is related to the fact that worldwide less than one quarter of hypertensive patients are adequately controlled for hypertension. Again, there are multiple reasons for these poor blood pressure (BP) control rates; however, most physicians would agree that patient compliance with their antihypertensive treatment is a major contributing factor. This is an area that we need to refocus on in our management of hypertensive patients. Issues such as safety, convenience, polypharmacy, cost, and education in the selection of antihypertensive agents are all critically important issues in the treatment of hypertensive patients. In addition, the level of patient involvement in their treatment seems to be essential in obtaining goal BP. Newer approaches to the management of hypertension such as earlier control of BP and the more aggressive use of low-dose combination therapy as first-line treatment of hypertension also need to be considered in our effort to improve BP control rates. Achieving goal BP in hypertensive patients is one of the most important clinical dilemmas facing physicians. There is little doubt that an improvement in control rates will result in substantial reductions in cardiovascular disease. Copyright 2003 Le Jacq Communications, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12671325      PMCID: PMC8101871          DOI: 10.1111/j.1524-6175.2003.00495.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  32 in total

1.  Maximizing Cardiorenal Benefit in the Management of Hypertension: Achieve Blood Pressure Goals.

Authors:  George L. Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  1999-10       Impact factor: 3.738

2.  The circadian blood pressure pattern in ambulatory normal subjects.

Authors:  M A Weber; J I Drayer; D K Nakamura; F A Wyle
Journal:  Am J Cardiol       Date:  1984-07-01       Impact factor: 2.778

3.  Continuation of initial antihypertensive medication after 1 year of therapy.

Authors:  B S Bloom
Journal:  Clin Ther       Date:  1998 Jul-Aug       Impact factor: 3.393

4.  Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group.

Authors:  F Messerli; W H Frishman; W J Elliott
Journal:  Am J Hypertens       Date:  1998-03       Impact factor: 2.689

5.  Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study.

Authors:  I Wiklund; K Halling; T Rydén-Bergsten; A Fletcher
Journal:  Blood Press       Date:  1997-11       Impact factor: 2.835

6.  Changes in antihypertensive therapy--the role of adverse effects and compliance.

Authors:  R Düsing; B Weisser; T Mengden; H Vetter
Journal:  Blood Press       Date:  1998-11       Impact factor: 2.835

7.  Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo.

Authors:  E Kuschnir; E Acuña; D Sevilla; J Vasquez; M Bendersky; J Resk; R Glazer
Journal:  Clin Ther       Date:  1996 Nov-Dec       Impact factor: 3.393

8.  The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.

Authors:  J L Chiasson; R Gomis; M Hanefeld; R G Josse; A Karasik; M Laakso
Journal:  Diabetes Care       Date:  1998-10       Impact factor: 19.112

Review 9.  Circadian variation and triggers of onset of acute cardiovascular disease.

Authors:  J E Muller; G H Tofler; P H Stone
Journal:  Circulation       Date:  1989-04       Impact factor: 29.690

10.  Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

Authors:  S MacMahon; R Peto; J Cutler; R Collins; P Sorlie; J Neaton; R Abbott; J Godwin; A Dyer; J Stamler
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321

View more
  18 in total

1.  Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.

Authors:  Steven G Chrysant
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Perspectives on Hypertension in the New England Cape Verdean Community.

Authors:  Samantha DeAndrade; Fadya El Rayess; Roberta Goldman
Journal:  J Racial Ethn Health Disparities       Date:  2017-03-10

3.  Acromegalic patients lost to follow-up: a pilot study.

Authors:  Leandro Kasuki; Nelma Verônica Marques; Maria José Braga La Nuez; Vera Lucia Gomes Leal; Renata N Chinen; Mônica R Gadelha
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

4.  Impact of educational mailing on the blood pressure of primary care patients with mild hypertension.

Authors:  Jacquelyn S Hunt; Joseph Siemienczuk; Dan Touchette; Nicola Payne
Journal:  J Gen Intern Med       Date:  2004-09       Impact factor: 5.128

5.  Predictors of first-fill adherence for patients with hypertension.

Authors:  Nirav R Shah; Annemarie G Hirsch; Christopher Zacker; G Craig Wood; Antoinette Schoenthaler; Gbenga Ogedegbe; Walter F Stewart
Journal:  Am J Hypertens       Date:  2009-01-29       Impact factor: 2.689

6.  Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study.

Authors:  Joerg Hasford; Detlef Schröder-Bernhardi; Marietta Rottenkolber; Karel Kostev; Gerhard Dietlein
Journal:  Eur J Clin Pharmacol       Date:  2007-08-14       Impact factor: 2.953

7.  Establishing the compliance in elderly women for use of a low level mechanical stress device in a clinical osteoporosis study.

Authors:  Marian T Hannan; Debbie M Cheng; Emily Green; Cherie Swift; Clinton T Rubin; Douglas P Kiel
Journal:  Osteoporos Int       Date:  2004-05-27       Impact factor: 4.507

8.  Assessment of drug-related problems and their impact on blood pressure control in patients with hypertension.

Authors:  Rana Abu Farha; Iman Basheti; Hassan Abu Al Ruz; Akram Alsaleh; Salah AbuRuz
Journal:  Eur J Hosp Pharm       Date:  2015-10-16

9.  Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment.

Authors:  Ying-Chang Tung; Yu-Chang Huang; Lung-Sheng Wu; Chee-Jen Chang; Pao-Hsien Chu
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-30       Impact factor: 3.738

Review 10.  Emerging insights in the first-step use of antihypertensive combination therapy.

Authors:  Keith Norris; Joel M Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-12       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.